ProShares Ultra NASDAQ Biotechnology
BIB
BIB
28 hedge funds and large institutions have $7.07M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
56% less capital invested
Capital invested by funds: $16M → $7.07M (-$8.88M)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Holders
28
Holding in Top 10
–
Calls
$1.99M
Puts
$2.85M
Top Buyers
| 1 | +$515K | |
| 2 | +$325K | |
| 3 | +$275K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$94.7K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$21.3K |
Top Sellers
| 1 | -$1.85M | |
| 2 | -$1.81M | |
| 3 | -$917K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$716K |
| 5 |
HF
HRT Financial
New York
|
-$536K |